The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.

scientific article published in February 1999

The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1177/00912709922007606
P698PubMed publication ID11563410

P2093author name stringMcLeod JF
Dunning BE
Karara AH
P2860cites workInteractions affecting drug absorptionQ40191959
Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).Q41140104
Effect of food on the bioavailability of SDZ DJN 608, an oral hypoglycemic agent, from a tablet and a liquid-filled capsule in the dog.Q51582537
Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.Q51611366
N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2Q69640963
Effects of N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) on insulin and glucagon secretion in isolated perfused rat pancreasQ72408696
Solubilizing properties of bile salt solutions. II. Effect of inorganic electrolyte, lipids, and a mixed bile salt system on solubilization of glutethimide, griseofulvin, and hexestrolQ72798646
P433issue2
P921main subjectbioavailabilityQ461809
pharmacodynamicsQ725307
P304page(s)172-179
P577publication date1999-02-01
P1433published inThe Journal of Clinical PharmacologyQ7743562
P1476titleThe effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
P478volume39

Reverse relations

cites work (P2860)
Q44744484A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes
Q36596836A review of nateglinide in the management of patients with type 2 diabetes.
Q38780360Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?
Q34549886Approaches to preventing mealtime hyperglycaemic excursions
Q34544816Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent
Q38167147Complications of diabetes therapy.
Q50192729Development and validation of analytical method for the estimation of nateglinide in rabbit plasma
Q36718446Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide
Q44579048Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes
Q44317938Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure
Q37184422Influence of food intake on the bioavailability and efficacy of oral calcitonin
Q34453173Insulinotropic meglitinide analogues
Q35557405Lessons learned from the clinical development of oral peptides
Q37775799Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials
Q30630393Meglitinide analogues in the treatment of type 2 diabetes mellitus
Q34059381Nateglinide
Q34449447Nateglinide therapy for type 2 diabetes mellitus
Q34390267Nateglinide: a new rapid-acting insulinotropic agent
Q44237132No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers
Q33368276Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin
Q42695854Pharmacokinetics of nateglinide in renally impaired diabetic patients
Q33975364Quo vadis nateglinide? Ten-year perspective
Q44341435Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection
Q40585698Separation and quantification of eight antidiabetic drugs on a high-performance liquid chromatography: its application to human plasma assay
Q44513024The effect of nateglinide taken with food on gastric emptying rates in healthy subjects